Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us
Progress Report

Investor Action on Antimicrobial Resistance progress report

As part of World Antimicrobial Awareness Week 2022, the Investor Action on Antimicrobial Resistance has today published its first progress report. The report highlights the types of efforts investors have so far undertaken, and can undertake in future, to help turn the tide on rising antimicrobial resistance (AMR) – an urgent public health challenge.

Date

21 November 2022

Direct links

Read the report

Launched at the World Economic Forum in 2020, the Investor Action on AMR initiative is a coalition between the Access to Medicine Foundation, the FAIRR initiative, the Principles for Responsible Investment and the UK Government Department of Health and Social Care. This initiative seeks to galvanise investor efforts to address global antimicrobial resistance (AMR).  

The Investor Action on AMR progress report, published on 21 November 2022, uses a series of case studies from the initiative’s Investor Partners to provide insights into what has been achieved so far, and how. The report demonstrates how asset owners, asset managers and development finance institutions can tangibly support global efforts to curb rising AMR, and why it is essential that more investors work to formally assess and integrate AMR risks and identify collaborative opportunities through a holistic and multi-sectoral “One Health” approach.

What's in the report?

About AMR

The materiality of AMR from a cross-sectoral “One Health” perspective, the range of risks and opportunities this presents, and tools – such as the Access to Medicine Foundation's AMR Benchmark – that investors can use to help better understand and engage on the topic.

Policy Developments

How national, international and multilateral action is growing in prominence as the systemic risk of AMR is increasingly recognised, and what this means for the investment community.

Investor case studies

The efforts of the initiative’s 16 Investor Partners to date, obstacles blocking progress and proposed solutions to these challenges. The case studies highlight concrete examples of investor action, such as guidance for adopting an AMR lens within investment decision-making, awareness raising, corporate engagement and macro-stewardship.

Key trends and looking ahead

This final section highlights findings from conversations with Investor Partners around the key trends and priorities that will drive further progress and impact in the coming months and years ahead.

Resource Centre

Read the viewpoints
Research

Harvard Business Review: How pharma can fix its reputation and its business at the same time

06 February 2017
Research

STAT: Global investors must support pharma solidarity and collaboration in response to COVID-19

28 September 2020

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved